









Markets
/
Stocks
/
nasdaq-phio
/

Phio Pharmaceuticals Corp

PHIO

0.920USD

+0.063+7.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

5.32MMarket Cap

LossP/E TTM



Phio Pharmaceuticals Corp

0.920

+0.063+7.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Phio Pharmaceuticals Corp

Currency: USD Updated: 2026-02-06

Key Insights

Phio Pharmaceuticals Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Phio Pharmaceuticals Corp's Score

Industry at a Glance

Industry Ranking

170 / 392

Overall Ranking

322 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Phio Pharmaceuticals Corp Highlights

StrengthsRisks

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Undervalued

The company’s latest PE is -0.43, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 799.30K shares, decreasing 33.14% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 87.63K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+1533.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Phio Pharmaceuticals Corp is 6.97, ranking 176 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.97

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Phio Pharmaceuticals Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Phio Pharmaceuticals Corp is 8.08, ranking 63 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.43, which is -110.53% below the recent high of 0.05 and -73.04% above the recent low of -0.74.

Score

Industry at a Glance

Previous score

8.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 170/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Phio Pharmaceuticals Corp is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 14.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+1533.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Phio Pharmaceuticals Corp

PHIO

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Phio Pharmaceuticals Corp is 3.49, ranking 362 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.16 and the support level at 0.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.38

Change

0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.026

Sell

RSI(14)

34.883

Neutral

STOCH(KDJ)(9,3,3)

28.598

Buy

ATR(14)

0.068

Low Volatility

CCI(14)

-136.991

Sell

Williams %R

73.631

Sell

TRIX(12,20)

-0.682

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.934

Sell

MA10

0.979

Sell

MA20

1.050

Sell

MA50

1.108

Sell

MA100

1.536

Sell

MA200

1.866

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Phio Pharmaceuticals Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 7.43%, representing a quarter-over-quarter decrease of 31.93%. The largest institutional shareholder is The Vanguard, holding a total of 87.63K shares, representing 0.81% of shares outstanding, with 1335.80% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Orca Capital GmbH

538.71K

-23.09%

Bitterman (Robert J)

293.04K

+3.53%

The Vanguard Group, Inc.

Star Investors

87.63K

+80.06%

Geode Capital Management, L.L.C.

57.91K

+0.37%

Nomura Investment Management Business Trust

50.00K

Carson (Lisa Cabott)

47.00K

Ferrara (Robert L)

38.77K

+147.45%

Cetera Investment Advisers LLC

33.50K

+3.08%

Bradford Patricia A

19.15K

+5340.91%

Lockshin (Curtis A)

16.56K

+4550.56%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Phio Pharmaceuticals Corp is 1.52, ranking 309 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.95. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.